quantisnow
FeedTopReportsPricing
⌘K
Live feed
16:21:04·295d
INSIDERFiling
SpringWorks Therapeutics Inc. logo

Director Alban Carlos returned 28,861 shares to the company, closing all direct ownership in the company (SEC Form 4)

SWTX· SpringWorks Therapeutics Inc.
Health Care
Original source

Companies

  • SWTX
    SpringWorks Therapeutics Inc.
    Health Care

Recent analyst ratings

  • Nov 20UpdateEvercore ISI$60.00
  • Feb 5UpdateGuggenheim$75.00
  • Dec 1UpdateBofA Securities$45.00
  • Sep 8UpdateJP Morgan$105.00
  • Aug 5UpdateHC Wainwright & Co.$137.00

Related

  • PR184d
    SpringWorks Therapeutics Announces Publication of Long-Term Efficacy and Safety Data from the Phase 3 DeFi Trial of OGSIVEO® (nirogacestat) in Adults with Desmoid Tumors in the Journal of Clinical Oncology
  • PR248d
    European Commission Grants Approval of OGSIVEO® (nirogacestat) for the Treatment of Adults with Desmoid Tumors
  • PR279d
    European Commission Grants Conditional Approval of EZMEKLY® (mirdametinib) for the Treatment of Adult and Pediatric Patients with NF1-PN
  • SEC286d
    SEC Form 15-12G filed by SpringWorks Therapeutics Inc.
  • SEC290d
    SEC Form SCHEDULE 13G filed by SpringWorks Therapeutics Inc.
  • INSIDER295d
    Chief Operating Officer Edris Badreddin returned 169,712 shares to the company, closing all direct ownership in the company (SEC Form 4)
  • INSIDER295d
    Director Lynch Daniel returned 93,004 shares to the company, closing all direct ownership in the company (SEC Form 4)
  • INSIDER295d
    Director Lewis-Hall Freda C returned 24,727 shares to the company, closing all direct ownership in the company (SEC Form 4)
quantisnow

Real-time market intelligence for retail investors. Press releases, filings, ratings, and insider flow - all in one stream.

All systems operational

Feeds

Press releasesAnalyst ratingsInsider tradingFDASECRSS feeds

Top lists

TrendingBy market capActive companiesAnalyst upgradesInsider purchasesFDA approvalsSEC filingsSectorsMarket reports

Company

AboutPricingPublish with usContact

Legal

Terms of usePrivacy policyCookie policy

© 2026 quantisnow.com · Democratizing insights since 2022